National ALS Registry Releases Updated Prevalence Estimates

National ALS Registry Releases Updated Prevalence Estimates

ArticlePress release
Health & Wellness
Diseases & Conditions
Contributed byLester Fahrner, MDApr 12, 2020

National ALS Registry Releases Updated Prevalence Estimates

The Agency for Toxic Substances and Disease Registry’s (ATSDR) National ALS Registry today released its second report on the prevalence of amyotrophic lateral sclerosis (ALS, commonly known as Lou Gehrig’s disease) in the United States for the years 2012 and 2013. The report shows the Registry identified 14,713 and 15,908 people, respectively, who met the surveillance case definition of ALS. The estimated ALS prevalence rate was 4.7 cases per 100,000 U.S. population for 2012 and 5.0 cases per 100,000 for 2013.

“It is likely the increased prevalence rate since the first report was issued does not reflect an actual increase in the number of ALS cases. Rather, this increase is more attributable to better detection methods used to identify ALS cases, along with an increased public awareness of the Registry,” said Paul Mehta, M.D., medical epidemiologist and principal investigator, National ALS Registry, and lead author of the report.

ALS was more common among whites, males, and people ages 60–69 years. The age groups with the lowest number of ALS cases were people ages 18–39 years and those ≥80 years. Males had a higher prevalence rate of ALS than females overall and across all data sources. These findings remained consistent between October 2010–December 2013 and are similar to findings from long-established ALS registries in Europe and from smaller-scale epidemiologic studies previously conducted in the United States.

The Registry is the only available data source that can be used to estimate the national prevalence for ALS in the United States. Because ALS is not a nationally notifiable disease, the Registry employs an innovative use of administrative data from Medicare, Medicaid, and the Veterans Health and Benefits Administrations to determine “definite” cases from a tested algorithm. The Registry also uses a secure web portal (https://wwwn.cdc.gov/als/) to identify cases that are not included in the national administrative databases.

The Registry also works with partner organizations such as the ALS Association and Muscular Dystrophy Association to increase public awareness and educate patients and caregivers about its activities. One such activity is the research notification mechanism, which informs Registry enrollees about new clinical trials and research studies for which they might be eligible.

The Registry funds research to better understand the cause or causes of ALS; to date, ATSDR has funded 13 different research studies. This fall, the Registry will launch the National ALS Biorepository. It will store samples from home visits (e.g., blood, hair, or saliva) and postmortem collection (e.g., brain, bone, spinal cord, cerebrospinal fluid, muscle, and skin). Currently, the few existing ALS biorepositories largely have samples that are from specific clinics or medical practices or from previous clinical trials in the United States. Specimens from the National ALS Biorepository will be collected from a geographically representative sample of people with ALS who are enrolled in the Registry and can be used for research such as genetic analysis, identification of biomarkers, and exposure to environmental toxic substances.

The 16-page report “Prevalence of Amyotrophic Lateral Sclerosis – United States, 2012-2013” can be found at MMWR on Thursday, August 4, 2016, at 1:00 PM.

###

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Was this article helpful

On the Article

Lester Fahrner, MD picture
Approved by

Lester Fahrner, MD

Chief Medical Officer, DoveMed Team

0 Comments

Please log in to post a comment.

Related Articles

Test Your Knowledge

Asked by users

Related Centers

Loading

Related Specialties

Loading card

Related Physicians

Related Procedures

Related Resources

Join DoveHubs

and connect with fellow professionals

Related Directories

Who we are

At DoveMed, our utmost priority is your well-being. We are an online medical resource dedicated to providing you with accurate and up-to-date information on a wide range of medical topics. But we're more than just an information hub - we genuinely care about your health journey. That's why we offer a variety of products tailored for both healthcare consumers and professionals, because we believe in empowering everyone involved in the care process.
Our mission is to create a user-friendly healthcare technology portal that helps you make better decisions about your overall health and well-being. We understand that navigating the complexities of healthcare can be overwhelming, so we strive to be a reliable and compassionate companion on your path to wellness.
As an impartial and trusted online resource, we connect healthcare seekers, physicians, and hospitals in a marketplace that promotes a higher quality, easy-to-use healthcare experience. You can trust that our content is unbiased and impartial, as it is trusted by physicians, researchers, and university professors around the globe. Importantly, we are not influenced or owned by any pharmaceutical, medical, or media companies. At DoveMed, we are a group of passionate individuals who deeply care about improving health and wellness for people everywhere. Your well-being is at the heart of everything we do.

© 2023 DoveMed. All rights reserved. It is not the intention of DoveMed to provide specific medical advice. DoveMed urges its users to consult a qualified healthcare professional for diagnosis and answers to their personal medical questions. Always call 911 (or your local emergency number) if you have a medical emergency!